European health regulators recommend restricted use of Cephalon’s sleep disorder, Provigil.
The drug is restricted to treating narcolepsy because its risks outweigh the benefits of the medicine for other uses.
According to the European Medicines Agency, doctors and patients should not use medicines that contain modafinil—which is an active ingredient of Provigil—for treating sleep disorders other than narcolepsy.
Cephalon will request a re-examination from the regulator.
Cephalon representatives say that the restriction of Provigil’s application will have minimal impact on the company’s earnings.
Analysts say that Cephalon will still meet its forecast for the year.

You must be logged in to post a comment.